Cambridge Major Laboratories and AAIPharma Services Announce Merger

GERMANTOWN, Wis. & WILMINGTON, N.C.--(BUSINESS WIRE)--Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, and AAIPharma Services Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development, and manufacturing services, have announced their intent to merge to form the premier global supplier of integrated CMC services. Financial terms of the merger were not disclosed. The merger is expected to close by the end of October 2013, subject to Hart-Scott-Rodino approval and other closing conditions. “The basis for the merger was to start with the right building blocks - a merger of two equals: two highly respected, market-leading firms with proven expertise in API development, analytical chemistry, and finished dosage forms,” said Brian Scanlan, CEO & President of CML. “We believe that we have a strong foundation to deliver superior customer-oriented solutions to expedite drug development and commercialization.”